Abcam, ab99236, Anti-PDE3A antibody

Size: 100µL
Rabbit Polyclonal PDE3A antibody. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human PDE3A aa 450-500.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human PDE3A aa 450-500. The exact immunogen used to generate this antibody is proprietary information.Q14432

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 6.8 - 7.4Preservative: 0.09% Sodium azideConstituents: Tris buffered saline, 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PDE3A also known as phosphodiesterase 3A regulates the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in cells by hydrolyzing these cyclic nucleotides. This enzyme with a molecular mass of approximately 133 kDa is expressed in tissues including the heart vascular smooth muscle and platelets. PDE3A activity influences contractility and promotes cell cycling and differentiation through its role in modulating signal transduction pathways.
Biological function summary
Phosphodiesterase 3A plays an important role in cardiac and vascular functions. It forms part of a signaling complex responsible for regulating cardiovascular responses. PDE3A manages intracellular cAMP and cGMP concentrations impacting vascular smooth muscle relaxation and platelet aggregation. The modulation of these signaling molecules by PDE3A contributes to maintaining normal heart rhythms and influencing blood pressure.
Pathways
Phosphodiesterase 3A is central to the cAMP and cGMP signaling pathways. PDE3A activity connects to the cardiac contractility pathway where it works alongside proteins like protein kinase A (PKA) which depends on cAMP levels. In the vascular system PDE3A activity is interlinked with the nitric oxide (NO) pathway where it modulates the effects of cGMP-dependent protein kinase (PKG). Together they orchestrate vascular actions such as smooth muscle contraction and vasodilation.
Research indicates that PDE3A contributes to cardiovascular conditions like heart failure and hypertension. In heart failure altered PDE3A activity can upset cAMP levels impacting cardiac contractility. Additionally genetic variants in PDE3A have been associated with hypertension due to their influence on blood vessel dynamics. Other proteins such as PKA in cardiac tissue and PKG in vascular tissues are involved in these conditions and their regulation by PDE3A adds another layer to understanding these diseases.